BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3480 related articles for article (PubMed ID: 23107319)

  • 1. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
    Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.
    Takahashi Y; Kohashi K; Yamada Y; Endo M; Setsu N; Ishii T; Yamamoto H; Iwamoto Y; Oda Y
    Hum Pathol; 2014 May; 45(5):984-93. PubMed ID: 24746202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
    Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
    Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.
    El-Habr EA; Levidou G; Trigka EA; Sakalidou J; Piperi C; Chatziandreou I; Spyropoulou A; Soldatos R; Tomara G; Petraki K; Samaras V; Zisakis A; Varsos V; Vrettakos G; Boviatsis E; Patsouris E; Saetta AA; Korkolopoulou P
    Virchows Arch; 2014 Oct; 465(4):473-85. PubMed ID: 25146167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
    Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
    PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.
    Liu D; Huang Y; Chen B; Zeng J; Guo N; Zhang S; Liu L; Xu H; Mo X; Li W
    Cancer; 2011 Aug; 117(16):3763-73. PubMed ID: 21387259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 174.